ES8104278A1 - Un procedimiento para la preparacion de derivados del indol. - Google Patents

Un procedimiento para la preparacion de derivados del indol.

Info

Publication number
ES8104278A1
ES8104278A1 ES489220A ES489220A ES8104278A1 ES 8104278 A1 ES8104278 A1 ES 8104278A1 ES 489220 A ES489220 A ES 489220A ES 489220 A ES489220 A ES 489220A ES 8104278 A1 ES8104278 A1 ES 8104278A1
Authority
ES
Spain
Prior art keywords
imidazolylalkyl
indoles
inhibition
thromboxane synthetase
action
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES489220A
Other languages
English (en)
Other versions
ES489220A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp
Original Assignee
Pfizer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp filed Critical Pfizer Corp
Publication of ES489220A0 publication Critical patent/ES489220A0/es
Publication of ES8104278A1 publication Critical patent/ES8104278A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DEL INDOL, DE FORMULA (I), Y SUS SALES DE ADICION DE ACIDOS FARMACEUTICAMENTE ACEPTABLES, DONDE R ELEVADO A 1 ES HIDROGENO O ALQUILO INFERIOR; R ELEVADO A 2 Y R ELEVADO A 3 PUEDEN SER HIDROGENO O DISTINTOS TIPOS DE RADICALES; X E Y PUEDEN SER DISTINTOS RADICALES. SE OBTIENE HACIENDO REACCIONAR UN COMPUESTO DE FORMULA (I), CON UNA BASE FUERTE, Y EL COMPUESTO ASI OBTENIDO SE HACE REACCIONAR NUEVAMENTE CON UN AGENTE ALQUILANTE DE FORMULA HAL-X-Y, DONDE HAL ES CLORO, BROMO Y YODO. ESTE COMPUESTO TIENE APLICACION EN EL TRATAMIENTO DE LA TROMBOSIS, ENFERMEDAD CARDIACA ESQUEMATICA, JAQUECA Y COMPLICACIONES VASCULARES DE LA DIABETES. *FORMULA*
ES489220A 1979-03-07 1980-03-05 Un procedimiento para la preparacion de derivados del indol. Expired ES8104278A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7908123 1979-03-07

Publications (2)

Publication Number Publication Date
ES489220A0 ES489220A0 (es) 1981-04-01
ES8104278A1 true ES8104278A1 (es) 1981-04-01

Family

ID=10503707

Family Applications (2)

Application Number Title Priority Date Filing Date
ES489220A Expired ES8104278A1 (es) 1979-03-07 1980-03-05 Un procedimiento para la preparacion de derivados del indol.
ES496889A Expired ES8205789A1 (es) 1979-03-07 1980-11-14 Un procedimiento para la preparacion de derivados del indol

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES496889A Expired ES8205789A1 (es) 1979-03-07 1980-11-14 Un procedimiento para la preparacion de derivados del indol

Country Status (36)

Country Link
US (1) US4273782A (es)
JP (1) JPS55133380A (es)
KR (1) KR850000760B1 (es)
AR (1) AR227015A1 (es)
AT (1) AT375366B (es)
AU (1) AU516957B2 (es)
BE (1) BE882113A (es)
CA (1) CA1120479A (es)
CH (1) CH649546A5 (es)
CS (1) CS253702B2 (es)
DD (1) DD149525A5 (es)
DE (1) DE3008632A1 (es)
DK (1) DK151884C (es)
ES (2) ES8104278A1 (es)
FI (1) FI66860C (es)
FR (1) FR2450832A1 (es)
GR (1) GR67237B (es)
HK (1) HK89884A (es)
HU (1) HU184727B (es)
IE (1) IE49542B1 (es)
IL (1) IL59524A (es)
IT (1) IT1218420B (es)
KE (1) KE3467A (es)
LU (1) LU82224A1 (es)
MY (1) MY8500285A (es)
NL (1) NL182959C (es)
NO (1) NO152217C (es)
NZ (1) NZ193052A (es)
PH (1) PH15198A (es)
PL (1) PL128296B1 (es)
PT (1) PT70914A (es)
SE (1) SE440778B (es)
SG (1) SG67284G (es)
SU (1) SU1277894A3 (es)
YU (1) YU41911B (es)
ZA (1) ZA801328B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414159A (en) * 1980-09-26 1983-11-08 E. I. Du Pont De Nemours & Co. Vinyl ether monomers and polymers therefrom
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US4460777A (en) * 1981-11-19 1984-07-17 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4539410A (en) * 1982-09-30 1985-09-03 Ciba-Geigy Corporation N-Substituted-2-(1-imidazolyl)indoles
US4436746A (en) 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
EP0239306B1 (en) 1986-03-27 1993-06-02 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
JPH0832679B2 (ja) * 1986-09-05 1996-03-29 理化学研究所 Ｎ―フタルイシド誘導体及びその製造法
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
KR920700210A (ko) * 1989-03-31 1992-02-19 기따미 가즈히꼬 신규 이미다졸 유도체, 그의 제법 및 그의 의약용도
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
WO1992005170A1 (en) * 1990-09-13 1992-04-02 Beecham Group Plc Indole ureas as 5 ht receptor antagonist
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
US5120749A (en) * 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
SG44510A1 (en) * 1991-12-18 1997-12-19 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
CA2109931A1 (en) * 1992-03-27 1993-10-14 Hiroshi Matsui Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor
US5538973A (en) * 1992-03-27 1996-07-23 Kyoto Pharmaceutical Industries, Ltd. Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
JPH0632913U (ja) * 1992-09-18 1994-04-28 三洋電機株式会社 床暖房用パネル
KR100584650B1 (ko) * 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산
AU2003297727A1 (en) * 2002-12-10 2004-06-30 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
AU2005296305A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease
US7803828B2 (en) * 2005-08-25 2010-09-28 Schering-Plough Corporation Functionally selective alpha2C adrenoreceptor agonists
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
RU2008149518A (ru) * 2006-05-16 2010-06-27 Декод Дженетикс, Ехф. (Is) Способ получения 7-(акрилоил) индолов
SI2046740T1 (sl) 2006-07-22 2012-12-31 Oxagen Limited Spojine s crth2 antagonistiäśno aktivnostjo
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2250161B1 (en) 2008-01-18 2013-10-16 Atopix Therapeutics Limited Compounds having crth2 antagonist activity
JP2011509990A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
AU2009325091A1 (en) * 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2012177782A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2019191410A1 (en) * 2018-03-29 2019-10-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors for the β-catenin / t-cell factor protein–protein interaction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125443C (es) * 1963-06-06
US3370063A (en) * 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3621027A (en) * 1968-03-18 1971-11-16 Endo Lab 1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
GR66544B (es) * 1977-08-26 1981-03-26 Wellcome Found
US4140858A (en) * 1977-12-19 1979-02-20 Warner-Lambert Company 3-(1H-imidazol-1-ylmethyl)-2-(disubstitutedaminomethyl)indoles and a method for their production
DE2960547D1 (en) * 1978-02-24 1981-11-05 Pfizer Ltd 3-(imidazol-1-ylalkyl)indoles as selective inhibitors of thromboxane synthetase,pharmaceutical compositions thereof, and methods for preparing them

Also Published As

Publication number Publication date
SE8001736L (sv) 1980-09-08
AU516957B2 (en) 1981-07-02
CS253702B2 (en) 1987-12-17
ES496889A0 (es) 1982-08-01
IL59524A0 (en) 1980-06-30
PH15198A (en) 1982-09-17
DE3008632A1 (de) 1980-10-16
YU41911B (en) 1988-02-29
PL222470A1 (es) 1980-12-01
ES489220A0 (es) 1981-04-01
NZ193052A (en) 1984-07-06
LU82224A1 (fr) 1980-06-06
US4273782A (en) 1981-06-16
IT1218420B (it) 1990-04-19
FI800672A (fi) 1980-09-08
KR850000760B1 (ko) 1985-05-25
SE440778B (sv) 1985-08-19
FR2450832B1 (es) 1983-04-22
IT8020399A0 (it) 1980-03-06
JPS6141513B2 (es) 1986-09-16
NO152217C (no) 1985-08-21
FR2450832A1 (fr) 1980-10-03
SU1277894A3 (ru) 1986-12-15
NL182959C (nl) 1988-06-16
KE3467A (en) 1984-11-09
HU184727B (en) 1984-10-29
NO152217B (no) 1985-05-13
IE49542B1 (en) 1985-10-30
BE882113A (fr) 1980-09-08
AT375366B (de) 1984-07-25
PL128296B1 (en) 1984-01-31
DK151884B (da) 1988-01-11
NL8001351A (nl) 1980-09-09
ATA125780A (de) 1983-12-15
CA1120479A (en) 1982-03-23
IL59524A (en) 1982-11-30
IE800453L (en) 1980-09-07
CH649546A5 (de) 1985-05-31
ZA801328B (en) 1981-03-25
JPS55133380A (en) 1980-10-17
DK151884C (da) 1988-06-13
DE3008632C2 (es) 1988-02-25
KR830001928A (ko) 1983-05-19
PT70914A (en) 1980-04-01
YU61480A (en) 1983-12-31
NO800650L (no) 1980-09-08
FI66860B (fi) 1984-08-31
AU5623180A (en) 1980-09-11
HK89884A (en) 1984-11-23
SG67284G (en) 1985-03-15
DK42580A (da) 1980-09-08
MY8500285A (en) 1985-12-31
DD149525A5 (de) 1981-07-15
GR67237B (es) 1981-06-25
FI66860C (fi) 1984-12-10
AR227015A1 (es) 1982-09-15
ES8205789A1 (es) 1982-08-01

Similar Documents

Publication Publication Date Title
ES8205789A1 (es) Un procedimiento para la preparacion de derivados del indol
ES8101556A1 (es) Un procedimiento para la preparacion de derivados de imida- zol.
ES8101557A1 (es) Un procedimiento para la preparacion de derivados de imida- zol.
HUT67436A (en) Process to prepare novel hydroxamic acid and n-hydroxyurea derivatives and pharmaceutical compn.s contg. them
DK8885A (da) N-heterocyclyl-4-piperidinaminderivater og fremgangsmaade til fremstilling deraf
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
WO2000021910A3 (en) 1,2-disubstituted cyclopropanes
EP0354777A3 (en) 3-(4-piperidine)-5-(2-sulfonylaminoethyl) indole derivatives
DK162883D0 (da) N-glucosylerede carboxylsyreamidderivater, fremgangsmade til fremstilling heraf samt deres anvendelse til pavirkning af organismens egen forsvarsmekanisme
ES8601187A1 (es) Un procedimiento para preparar un derivado de carbostirilo
ES482097A1 (es) Procedimiento para preparar derivados acilicos de carnitina.
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
IE800359L (en) Imidazole thromboxane synthetase inhibitors
EP0068563A3 (en) Heterocyclic acetic acid compounds and compositions for treating bone diseases
ES465152A1 (es) Procedimiento para la obtencion de derivados del acido %- (aminoacetil)fenoxiacetico.
HK1050141A1 (en) Inhibitor for 20-hete-yielding enzyme
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
JPS5283380A (en) Synthesis of thiocarbostyril derivatives
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
PT72359B (fr) Procede de preparation de nouveaux derives de dihydro-i,3- imidazo<1,2,-b->pyrydazines avec application en therapeutique
ES481109A1 (es) Un metodo de preparacion de un extracto de stephania cepha- rantha.
IE43863L (en) Imidazole derivatives
ES483412A1 (es) Un procedimiento para la preparacion de nuevos derivados de-minidazol.
AU4288285A (en) Novel pharmaceutical compositions having immuno-suppressive properties

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970612